Fate Therapeutics - 53 Year Dividend History | FATE
Historical dividend payout and yield for Fate Therapeutics (FATE) since 1971. The current TTM dividend payout for Fate Therapeutics (FATE) as of April 18, 2024 is $0.00. The current dividend yield for Fate Therapeutics as of April 18, 2024 is 0.00%.
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Biomedical and Genetics |
$0.600B |
$0.064B |
|
Fate Therapeutics is a clinical-stage biopharmaceutical company, which is focused on the development of programmed cellular immunotherapies for cancer and immune disorders.? The company uses various therapeutic approaches for cell programming to develop cell therapies. The company programs cells of the blood and immune system, including natural killer (NK) cells, T cells and CD34 cells, and is advancing a pipeline of programmed cellular immunotherapies. It uses pharmacologic modulators, such as small molecules, to enhance the biological properties and therapeutic function of healthy donor-sourced cells ex vivo before the product candidates are administered to a patient. It also uses human induced pluripotent stem cells (iPSCs) to generate a clonal master iPSC line having preferred biological properties and direct the fate of the clonal master iPSC line to create its cell therapy product candidate.
|
| Stock Name |
Country |
Market Cap |
PE Ratio |
